Board Meeting Outcome for Approval Of Unaudited Financial Results For The Half Year Ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aptus Pharma reported strong H1 FY26 results. Revenue from operations rose to Rs. 1,437.75 lakhs, up 47.38% from Rs. 975.57 lakhs in H1 FY25. EBITDA grew 36.12% to Rs. 294.55 lakhs, while PAT climbed 33.81% to Rs. 174.69 lakhs. However, both EBITDA margin (20.49%, down 169 bps) and PAT margin (12.15%, down 123 bps) compressed year-on-year due to higher operating costs. The balance sheet strengthened significantly with reserves surging to Rs. 1,484 lakhs from Rs. 193 lakhs and cash rising to Rs. 1,428 lakhs, aided by IPO proceeds of Rs. 1,302 lakhs now fully utilized. Short-term borrowings declined to Rs. 600 lakhs from Rs. 774 lakhs. The auditors (ABKB&Co.) issued a clean limited review report with no qualifications.
Strong top-line and bottom-line growth signals healthy business momentum, but margin compression may concern investors focused on profitability quality. Improved liquidity and reduced debt are positives for shareholders, though negative operating cash flow (-Rs. 92 lakhs) warrants monitoring.